Overview
- Oppenheimer raised its target to $16, Needham to $17, and HC Wainwright to $25, with all eight covering analysts rating the stock Buy.
- Management increased 2026 revenue guidance to $170–$180 million during Investor Day.
- Preliminary Q4 2025 revenue was $27–$29 million and full‑year 2025 revenue was $47.6–$49.6 million, exceeding prior expectations.
- Order backlog reached $65.3 million as of Dec. 31, a 180% jump from mid‑November, and cash exceeds $1.5 billion following a $1 billion equity raise.
- Shares have surged more than 500% in 2025, and the stock trades at a forward price‑to‑sales ratio near 31 versus an industry average of about 2.25.